Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

April 13, 2022

Study Completion Date

April 13, 2022

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

WX-081

WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.

DRUG

Bedaquiline

This licensed drug will be used in arm F as positive comparator.

DRUG

Standard treatment

Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.

DRUG

Multi-drug background treatment (MBT)

MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.

Trial Locations (1)

101149

Beijing Chest Hospital affiliated to Capital Medical University, Beijing

All Listed Sponsors
lead

Shanghai Jiatan Pharmatech Co., Ltd

INDUSTRY

NCT04608955 - Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 | Biotech Hunter | Biotech Hunter